If you’ve been turning to melatonin to fix your sleepless nights, you may want to pause before popping your next dose. The hormone can be helpful – but only when used correctly. Wrong timing or excessive amounts can do the opposite of what…
Blog
-
Fashion Trust Arabia Names Prize Winners in Qatar
The Fashion Trust Arabia, a non-profit fund supporting emerging design talent from the Middle East and North Africa, returned to Doha, Qatar for its seventh edition on Saturday. Six of the region’s up-and-coming designers, and one guest country…
Continue Reading
-
Cardiovascular disease risk following radiotherapy among breast cancer survivors: a nationwide cohort study in South Korea | Breast Cancer Research
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Continue Reading
-
Sunday in Navy Varsity Athletics – Naval Academy Athletics
- Sunday in Navy Varsity Athletics Naval Academy Athletics
- Rifle Outshoots Army on the Road for Fifth Victory this Season University of Alaska Fairbanks Athletics
- 8 Navy Rifle Team Faces Tough Matches This Sunday Against #9 Alaska Fairbanks and #16…
Continue Reading
-
Study Suggests Dark Energy Weakening, Slowing Universe Expansion
In the vast expanse of cosmology, few concepts have stirred as much intrigue and debate as dark energy. For over two decades, it has been the cornerstone explanation for the universe’s accelerating expansion, a mysterious force…
Continue Reading
-
UK launches critical minerals strategy to reduce dependency on China | Critical minerals
Keir Starmer has announced a critical minerals and rare earths strategy to build resilience against China, which has a stranglehold on supplies of materials including magnets critical to everything from car doors to fridges.
“For too long, Britain has been dependent on a handful of overseas suppliers, leaving our economy and national security exposed to global shocks,” the prime minister said.
The critical minerals initiative comes with a £50m fund to boost production at tungsten and lithium mines in Cornwall. Europe’s largest deposits of lithium are in Cornwall, and the EU singled out the county’s tungsten mine for potential financial support this summer.
The strategy follows a six-week standoff between China and the EU over the supply of chips used in the car industry, underlining how Beijing is willing to use trade in critical materials for political purposes.
The UK and the US are now battling to reduce their dependence on China, but the production of rare earths and critical minerals can take years and hundreds of millions of pounds in investment.
Lithium supplies exist all over Europe, but the raw material needs to be refined into lithium hydroxide, a crystal-like ingredient used to create the charge in car batteries.
Europe’s only lithium hydroxide refinery, in Germany, has taken five years to build and £150m in investment, showing the scale of the funding needed.
Last week the EU’s industry commissioner, Stéphane Séjourné, conceded that the bloc was far behind the US, which he said had “a business department that buys stocks of critical materials” before everyone else. “They often buy them from under our noses,” he said.
Earlier this year, Britain struck a minerals cooperation deal with Saudi Arabia aimed at bolstering supply chains, opening doors for British firms and drawing fresh investment into the UK. Rare-earth minerals are essential for smartphones and electric vehicles and increasingly crucial for building datacentres that power artificial intelligence.
The UK’s strategy seeks to ensure no more than 60% of any one critical mineral comes from a single partner country by 2035, according to a statement.
Starmer described critical minerals as “the backbone of modern life and our national security” and argued that boosting domestic production and recycling would help shield the economy and support efforts to lower living costs.
The government said the UK currently produced 6% of its critical mineral needs domestically. Under the plan, it wants to expand domestic extraction and processing, with a particular focus on lithium, nickel, tungsten and rare earths. It aims to produce at least 50,000 tonnes of lithium in the UK by 2035.
Continue Reading
-
Exploring Valuation After Strong Year-to-Date Share Price Gains
Lloyds Banking Group (LSE:LLOY) stock has seen some movement recently, drawing interest from investors as they weigh the company’s latest returns and prospects. Let’s take a closer look at what is behind the shifts in performance.
See our latest analysis for Lloyds Banking Group.
Despite a dip over the past week, Lloyds Banking Group’s share price is still up significantly for the year, with impressive momentum driving a 58.3% year-to-date price return and a remarkable 68.1% one-year total shareholder return. This surge suggests growing confidence in the stock’s outlook, even as the pace of gains has moderated recently.
If Lloyds’ strong run has you watching for the next potential outperformer, now is the perfect time to discover fast growing stocks with high insider ownership
But is this surge just catching up to Lloyds’ fair value, or does the bank’s recent climb signal that future growth is already priced in? Could there still be a compelling buying opportunity, or is the market ahead of itself?
Lloyds Banking Group’s narrative fair value estimate stands above the last close, suggesting upside potential if analysts’ long-range projections play out. The latest market enthusiasm aligns with expectations of stronger growth and returns.
Lloyds’ significant progress in digital transformation, including expanding mobile-first services for 21 million users, rolling out a new digital remortgage journey, and leveraging AI innovation, continues to drive operating cost reductions and enhances efficiency. This positions the company to support sustained long-term margin expansion and higher earnings.
Read the complete narrative.
Want to know the drivers behind this valuation? The narrative hinges on a bold pivot in earnings quality, technology leadership, and rising profit margins. What happens next could reshape the story for shareholders. Curious about the financial leaps and market expectations behind this verdict? See the full narrative for the key assumptions that underpin the fair value calculation.
Result: Fair Value of $0.94 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, risks remain, including Lloyds’ heavy reliance on the UK economy and intensifying digital competition. Either of these factors could challenge the bank’s growth path.
Find out about the key risks to this Lloyds Banking Group narrative.
Looking beyond fair value estimates, Lloyds trades at a price-to-earnings ratio of 14.8x. This is notably higher than both its UK bank peers at 10.6x and the broader European banks average of 9.8x. Compared to a fair ratio of 9.7x, Lloyds also appears more expensive. This raises questions about whether expectations have run too far ahead. Will the market eventually demand stronger growth to justify this premium?
Continue Reading
-
Metabolic reprogramming and mitochondrial dysfunction underlie β gonia arrest and niche cell dysfunction in sterile triploid oysters
Cinalli, R. M., Rangan, P. & Lehmann, R. Germ cells are forever. Cell 132, 559–562 (2008).
Nakajima, K. Be my baby: patterning toward plant germ cells. Curr. Opin. Plant Biol. 41, 110–115…
Continue Reading
-
World Boxing: Gennady Golovkin elected president of federation
Golovkin won the Olympic silver medal in the middleweight division at the 2004 Games in Athens.
He also held world and Asian titles as an amateur before stepping up to the professional ranks, in which he held a middleweight world title and is…
Continue Reading
-
GSK Shares Surge 31% in 2025 Amid Vaccine Breakthroughs Is There Still Value?
-
Wondering if GSK could be a hidden value opportunity or just another stock riding pharma’s global upswing? You are in the right place for a deep dive into what the numbers really say.
-
GSK’s shares have climbed 31.3% so far this year and are up nearly 40% over the past 12 months. This puts a bright spotlight on its growth and changing risk profile.
-
The buzz around GSK this year has been fueled by positive developments in its pipeline, strategic partnerships, and growing optimism about regulatory milestones. Headlines highlighting advances in its vaccine division and expansion into new markets have amplified investor excitement far beyond the usual quarterly news cycle.
-
Our latest check gives GSK a valuation score of 5 out of 6, which means it screens as undervalued on nearly every metric. In this article, we will walk through exactly how that number is calculated using the most common valuation methods. Stay tuned for a fresh approach to valuation at the end that is changing how savvy investors decide what is truly worth owning.
GSK delivered 39.1% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.
The Discounted Cash Flow (DCF) model estimates the value of a company by projecting its future cash flows and then discounting them back to today’s value. This approach aims to determine what those future pounds are worth in present terms.
GSK’s current Free Cash Flow stands at £5.13 billion. Analyst estimates forecast this figure growing steadily, with Simply Wall St projections indicating Free Cash Flow will reach nearly £7.99 billion by 2029 and over £9.85 billion a decade out. While analysts typically provide forecasts for up to five years, Simply Wall St extends the projection further by applying reasonable industry growth trends to cash flow estimates over a longer period.
Based on the DCF model, the estimated intrinsic value for GSK is £45.51 per share. This figure represents a substantial 60.7% discount compared to the current trading price. According to these cash flow projections, the market may be significantly undervaluing GSK’s shares at this time.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests GSK is undervalued by 60.7%. Track this in your watchlist or portfolio, or discover 927 more undervalued stocks based on cash flows.
GSK Discounted Cash Flow as at Nov 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for GSK.
For established, profitable companies such as GSK, the Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics. The PE ratio gauges how much investors are willing to pay for each pound of earnings, making it a practical benchmark for companies that consistently generate profits.
Continue Reading
-
